Amgen licenses Boehringer MM candidate

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted Amgen Inc. (NASDAQ:AMGN) global rights to develop and commercialize multiple myeloma candidate BI 836909 (AMG 420). Financial details were not disclosed.

BI 836909, a bispecific T cell engager (BiTE) that targets tumor necrosis factor (TNF) receptor superfamily member 17 ( BCMA; TNFRSF17; CD269), is in Phase I testing. ...